Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
08 Mai 2023 - 2:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
focused on discovering and developing potential best-in-class
medicines for serious and rare diseases, today announced a new
partnership with Enable Injections, a company developing and
manufacturing the enFuse® innovative wearable drug delivery system
for volumes of up to 25mL.
“As we expand our pipeline beyond TED and assess the unmet needs
of patients living with other serious and rare diseases, it’s clear
that convenient drug delivery is an important issue,” said Scott
Myers, President and CEO of Viridian. “We believe Enable’s
proprietary technology can contribute meaningfully to our goal of
delivering therapeutic advances while reducing patient treatment
burden as well.”
“Enable Injections is excited to partner with Viridian to
utilize the enFuse® technology to enhance the patient experience,”
said Michael D. Hooven, Enable Injections' Chairman and CEO. “The
enFuse® on-body delivery system was engineered with the patient in
mind—the hidden needle and hands-free delivery allows patients to
have increased flexibility, improved convenience, and the ability
to administer medication discreetly, whether at home via
self-administration or in the clinic.”
This partnership, which applies exclusively to areas outside of
Viridian's established TED portfolio, underscores the company's
commitment to patient-centric innovation.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on
engineering and developing potential best-in-class medicines for
patients with serious and rare diseases. Viridian’s expertise in
antibody discovery and engineering enables it to develop
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The Company
has initiated its first global Phase 3 trial called ‘THRIVE’ to
evaluate the safety and efficacy of VRDN-001 in patients with
active TED. Viridian is also evaluating VRDN-001 in a Phase 2
proof-of-concept trial in patients with chronic TED. In addition to
its program for intravenously administered VRDN-001, the Company is
advancing three candidates for its subcutaneous strategy with the
goal of providing a more conveniently administered therapy to
patients with TED. Viridian is also developing multiple preclinical
assets in autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and twitter.
About Enable Injections
Cincinnati-based Enable Injections is a global healthcare
innovation company developing and manufacturing drug delivery
systems designed to improve the patient experience. Enable's
body-worn enFuse® delivers high-volume pharmaceutical and
biologic therapeutics via subcutaneous administration, with the aim
of improving convenience, supporting superior outcomes, and
advancing healthcare system economics. The investigational enFuse
system has not been approved for use by any regulatory agency and
is currently not approved for commercial use. For more information,
please visit www.enableinjections.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as, but not limited to, "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "might," "plan,"
"potential," "predict," "project," "should," "target," "will," or
"would" or other similar terms or expressions that concern the
Company’s expectations, plans and intentions. Forward-looking
statements include, without limitation, statements regarding the
Company’s expectations, strategies, plans and intentions.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on the
Company’s current beliefs, expectations, and assumptions. New risks
and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. No representations
or warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements. Such forward-looking
statements are subject to a number of material risks and
uncertainties, including our belief in the potential benefit of the
Enable Injections technology and those risks set forth under the
caption “Risk Factors” in the Company’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission (SEC)
on March 9, 2023 and other subsequent disclosure
documents filed with the SEC. Any forward-looking statement
speaks only as of the date on which it was made. Neither the
Company, nor its affiliates, advisors, or representatives,
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date hereof.
Contacts
Investors:Louisa Stone, 508-808-2400Manager, Investor
RelationsIR@viridiantherapeutics.com
Todd James, 617-272-4691Senior Vice President, Corporate Affairs
and Investor RelationsIR@viridiantherapeutics.com
Media:Matt Fearer, 617-272-4605Vice President, Corporate
CommunicationsMedia@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Okt 2023 bis Okt 2024